Biotest AG
BIESF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $726 | $685 | $516 | $516 |
| % Growth | 6.1% | 32.6% | 0.1% | – |
| Cost of Goods Sold | $502 | $404 | $391 | $435 |
| Gross Profit | $224 | $280 | $125 | $81 |
| % Margin | 30.8% | 40.9% | 24.2% | 15.7% |
| R&D Expenses | $57 | $75 | $51 | $55 |
| G&A Expenses | $38 | $31 | $32 | $30 |
| SG&A Expenses | $88 | $81 | $81 | $81 |
| Sales & Mktg Exp. | $50 | $50 | $49 | $51 |
| Other Operating Expenses | -$16 | -$23 | $0 | $0 |
| Operating Expenses | $129 | $137 | $133 | $133 |
| Operating Income | $95 | $144 | -$17 | -$47 |
| % Margin | 13% | 21% | -3.2% | -9.1% |
| Other Income/Exp. Net | -$48 | -$37 | -$14 | -$16 |
| Pre-Tax Income | $47 | $106 | -$31 | -$63 |
| Tax Expense | $20 | -$21 | $1 | $1 |
| Net Income | $26 | $127 | -$32 | -$63 |
| % Margin | 3.6% | 18.6% | -6.1% | -12.3% |
| EPS | 0.71 | 3.21 | -0.8 | -1.61 |
| % Growth | -77.9% | 501.2% | 50.3% | – |
| EPS Diluted | 0.71 | 3.21 | -0.8 | -1.6 |
| Weighted Avg Shares Out | 37 | 40 | 40 | 40 |
| Weighted Avg Shares Out Dil | 40 | 40 | 40 | 40 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $1 | $0 |
| Interest Expense | $33 | $40 | $24 | $13 |
| Depreciation & Amortization | $41 | $36 | $36 | $31 |
| EBITDA | $120 | $182 | $25 | -$18 |
| % Margin | 16.6% | 26.6% | 4.8% | -3.5% |